Canine lymphoma is the most prevalent form of cancer in dogs and has a high mortality rate, prompting research into potential treatments.
The inhibitor dynasore was found to significantly reduce the viability of various canine lymphoma cell lines while inducing apoptosis specifically in cancerous cells, but not in healthy cells.
The study suggests that dynasore could be an effective new treatment option for canine lymphoma by triggering a DNA damage response in cancer cells.
Endocytosis is crucial for cancer growth and spread, and its inhibitors can reduce cancer cell proliferation and migration.
The endocytosis inhibitor dynasore was found to decrease cell viability in various cancer types, particularly hematopoietic cancers, by inducing apoptosis and delaying cell cycle progression.
Dynasore activates the ATR-Chk1 DNA damage response, indicating potential DNA replication stress, and combining it with an ATR inhibitor enhances the effects, highlighting a possible new approach for cancer treatment.